George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill...
Company announcement, Inside information, Helsinki, 1 July 2021 at 14.00 (EET) Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") provides an...
WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing...
Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and...
ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization...
AFM13 monotherapy: Reported positive outcome from the preplanned interim analysis for the registration-directed trial in PTCL; enrollment expected to be...
Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligoCompany progressing...
Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24...
– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel...
Dr Barry Marks Chiropractor announced that they are now providing an updated range of after-accident care treatments to patients in...
Company Announcement COPENHAGEN, Denmark; July 01, 2021 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed...
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY...
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill...
Press ReleaseNicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma TrialResults Demonstrating Superior Efficacy to Current...
Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpointsiOver 90% reduction in mean...
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s...
Ad Hoc Announcement Pursuant to Art. 53 LR Data could enable acceleration of lead optimization using computer aided drug discovery...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia...
REGULATED INFORMATION The EIB financing to be used for Bone Therapeutics’ allogeneic cell therapy platform ALLOB and potential commercialization of...